Pfizer And MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid
Tiered Pricing To Allow Equitable Access To Oral Antiviral
An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it necessarily represents a good deal for lower-income countries.
You may also be interested in...
A Year Of Paxlovid - Where Is The Licensed Generic?
A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.
Shionogi and Medicines Patent Pool Partner To Bring COVID-19 Anti-Viral To 117 Countries
A license agreement between Shionogi and the Medicines Patent Pool aims to widen access to Shionogi’s oral COVID-19 anti-viral ensitrelvir in low to middle-income countries. The investigational drug reduced Omicron-related symptoms in a recent Phase III trial.
WHO Urges Pfizer To Broaden Generic Paxlovid MPP Deal
As Pfizer’s Paxlovid joins the World Health Organization’s prequalification list, the organization has passed down several recommendations to the US-based Big Pharma, including expanding the scope of countries supplied under an MPP generic licensing agreement.